Digital tools to track multiple sclerosis activity and progression
Observes 700 people with multiple sclerosis using two smartphone monitoring apps.
Plain-language title generated from the registry record
Registry title: Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis
Key facts
- Where
- Amsterdam, Arnhem, and Geleen, NetherlandsSee the 3 sites
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsNo longer taking part
- Rijnstate ArnhemArnhem, NetherlandsNo longer taking part
- Zuyderland Medical CenterGeleen, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC, location VUmc
- Trial code
- NCT06627465
- Record updated
- 4 October 2024
- Original description
The Connect-MS is multicentre real-world observational cohort study wherin the outcomes of standard care digital monitoring of 700 patients with multiple sclerosis (including all subtypes) are recorded over a follow-up period of two years. Patients use the MS sherpa and NeuroKeys applications. Outcomes are related to the utilisation of digital biomarkers including the adherence to digital monitoring and the impact digital outcomes have on clinical decision making, the effect of digital monitoring on healthcare consumption, and the ability of these technological biomarkers to detect clinical outcomes on the short and long term. Most recorded variables are part of the standard care, however participants of this study are also subject to additional questionnaires regarding the consumption of healthcare and the influence of digital monitoring on decision making during clinical consultation.Read full original descriptionShow less
Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis
The Connect-MS is multicentre real-world observational cohort study wherin the outcomes of standard care digital monitoring of 700 patients with multiple sclerosis (including all subtypes) are recorded over a follow-up period of two years. Patients use the MS sherpa and NeuroKeys applications. Outcomes are related to the utilisation of digital biomarkers including the adherence to digital monitoring and the impact digital outcomes have on clinical decision making, the effect of digital monitoring on healthcare consumption, and the ability of these technological biomarkers to detect clinical outcomes on the short and long term. Most recorded variables are part of the standard care, however participants of this study are also subject to additional questionnaires regarding the consumption of healthcare and the influence of digital monitoring on decision making during clinical consultation.
In order to be eligible to participate in this study, a subject must meet all of the following criteria:; Have signed non-WMO informed consent; Be able to comply with the study protocol, as judged by the investigator; Have a minimum age of 18 years; Have a definite diagnosis multiple sclerosis (either RRMS, SPMS or PPMS) according to the revised 2017 McDonald criteria. (Thompson et al., 2018); Willing and able to install and use MS Sherpa and NeuroKeys on a privately-owned cell phone; Since this is an observational cohort study, concomitant participation in any intervention trial is allowed.